Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension and Primary Hypercholesterolemia
NCT05930028Phase 3Completed
- Sponsor
- Boryung
- Start
- Jul 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fimasartan, ezetimibe, atorvastatin in essential hypertension, hypercholesterolemia, sponsored by Boryung. Started Jul 2023; status: completed.
02
Drugs
fimasartanezetimibeatorvastatin
03
Conditions
essential hypertensionhypercholesterolemia
Beyond the preview
Go deeper on NCT05930028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930028.